ESMO 2022 Conference Coverage


 

Lecture Summary - ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-2: Evaluating the Efficacy & Safety of Fruquintinib in Refractory mCRC

13 views
September 30, 2022
Comments 0
Login to view comments. Click here to Login